Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer.

ABSTRACT:

Purpose

Oncology clinical practice guidelines recommend bone-modifying agents (BMAs) to decrease skeletal-related events for patients with metastatic castration-resistant prostate cancer (mCRPC) and against BMAs to decrease skeletal-related events in metastatic castration-sensitive prostate cancer (mCSPC). Previous studies have identified gaps in guideline-concordant BMA use, but interprovider variation is poorly understood.

Methods

We conducted a multicenter, retrospective, cohort study of patients diagnosed with prostate cancer and bone metastases during 2020-2021. The sample included three health systems in the Northeastern United States: two community-based networks and one academic cancer center. Patient characteristics and BMA use (zoledronic acid and denosumab) were a

SUBMITTER: Mitchell AP 

PROVIDER: S-EPMC12614842 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature